Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$COR
Other Pharmaceuticals
Health Care
Get the next $COR alert in real time by email
false 0001140859 0001140859 2025-01-02 2025-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 2, 2025

 

 

 

Cencora, Inc.

 

 

(Exact name of Registrant, as specified in its charter)

 

Delaware   1-16671   23-3079390
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
         

1 West First Ave.
Conshohocken, PA

     

 

19428-1800

(Address of principal executive       (Zip Code)
offices)        

 

Registrant’s telephone number, including area code:   (610) 727-7000

 

Not Applicable

 

Former name or address, if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock COR New York Stock Exchange
(NYSE
)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company     ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

 

 

 

 

 

Item 2.01. Completion of Acquisition or Disposition of Assets

 

As previously disclosed in the Current Report on Form 8-K filed by Cencora, Inc. (the “Company”) with the Securities and Exchange Commission on November 8, 2024, the Company entered into a definitive agreement to acquire Retina Midco, Inc. (“Retina Consultants of America” or “RCA”), a leading management services organization of retina specialists, from Webster Equity Partners. On January 2, 2025, the Company completed the acquisition and RCA became a subsidiary of the Company. The Company acquired an interest in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in RCA. The Company’s cash outlay at closing was $4.4 billion, which amount is subject to a customary post-closing purchase price adjustment.

 

Item 7.01. Regulation FD Disclosure

 

On January 2, 2025, the Company issued a news release announcing the completion of the acquisition of RCA, a copy of which is furnished with this Current Report as Exhibit 99.1 and is incorporated herein by reference.

 

The information set forth in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   News Release of Cencora, Inc., dated January 2, 2025.
104   Cover Page Interactive Data File (formatted as inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Cencora, Inc.

   
Date: January 2, 2025 By: /s/ James F. Cleary
    Name: James F. Cleary
    Title: Executive Vice President and Chief Financial Officer

 

 

 

Get the next $COR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COR

DatePrice TargetRatingAnalyst
12/4/2024$280.00Outperform
Mizuho
9/18/2024$275.00 → $245.00Buy → Neutral
BofA Securities
2/26/2024$261.00Outperform
Leerink Partners
1/3/2024$242.00Overweight
Barclays
12/14/2023$213.00Equal Weight
Wells Fargo
12/14/2021$162.00 → $170.00Buy → Neutral
Citigroup
11/26/2021$136.00 → $170.00Sector Perform
RBC Capital
11/16/2021Underweight → Equal-Weight
Barclays
More analyst ratings

$COR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

    $COR
    Other Pharmaceuticals
    Health Care
  • Cencora Completes Acquisition of Retina Consultants of America

    Acquisition Advances Specialty Leadership Adjusted Diluted EPS Guidance Range Raised to $15.15 to $15.45 for Fiscal 2025 Cencora, Inc. (NYSE:COR) today announced the completion of its previously announced acquisition of Retina Consultants of America ("RCA"), a leading management services organization (MSO) of retina specialists. Cencora has acquired an interest in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in the company. After giving effect to the equity rollover, a cash capitalization of RCA that Cencora has made, the payment of transaction fees and expenses and the repayment of debt, Cencora's cash o

    $COR
    Other Pharmaceuticals
    Health Care
  • Cencora Closes $1.8 Billion Senior Notes Offering

    Cencora, Inc. (NYSE:COR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the "2027 Notes"), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the "2029 Notes") and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the "2035 Notes" and, together with the 2027 Notes and the 2029 Notes, the "Notes"), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the "SEC") on November 26, 2024. Cencora

    $COR
    Other Pharmaceuticals
    Health Care

$COR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$COR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$COR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$COR
SEC Filings

See more

$COR
Leadership Updates

Live Leadership Updates

See more
  • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    $COR
    Other Pharmaceuticals
    Health Care
  • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

    The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

    $AXS
    $COR
    $POR
    $WTT
    Property-Casualty Insurers
    Finance
    Other Pharmaceuticals
    Health Care

$COR
Financials

Live finance-specific insights

See more
  • Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access t

    $COR
    Other Pharmaceuticals
    Health Care
  • Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

    Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni

    $COR
    Other Pharmaceuticals
    Health Care
  • Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the

    $COR
    Other Pharmaceuticals
    Health Care

$COR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more